999三九品牌怎么样 申请店铺

我要投票 999三九在中草药行业中的票数:2140 更新时间:2026-01-08
999三九是哪个国家的品牌?「999三九」是 华润医药控股有限公司 旗下著名品牌。该品牌发源于广东,由创始人王春城在2007期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力999三九品牌出海!将品牌入驻外推网,定制999三九品牌推广信息,可以显著提高999三九产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

999三九怎么样

华润三九医药股份有限公司(简称“华润三九”)是大型国有控股医药上市公司,前身为深圳南方制药厂。1999年4月21日,发起设立股份制公司。2000年3月9日在深圳证券交易所挂牌上市,股票代码000999。公司于2007年11月底正式进入华润集团。2010年2月,公司名称由“三九医药股份有限公司”正式变更为"华润三九医药股份有限公司"。

华润三九主要从事医药产品的研发、生产、销售及相关健康服务。“999”品牌是中国驰名商标。公司核心产品在国内药品市场上具有相当高的占有率和知名度。三九胃泰、999感冒灵、999皮炎平、999小儿氨酚、999正天丸、999强力枇杷露、气滞胃痛颗粒、999参附注射液、999参麦注射液、舒血宁注射液、华蟾素、999新泰林(注射用五水头孢唑啉钠)、999中药配方颗粒等,单品种年销售均超过亿元人民币。其中,999感冒灵系列销量连续五年位居感冒药市场第一,2011年实现销售额13.6亿元。

2011年,华润三九实现营业收入55.25亿元,较上年同期增长26.58%,实现了公司通过外延式发展促进业务增长的目标。由于成本费用上涨,2011年实现归属于母公司所有者的净利润7.6亿元,同比上年略有降低;经营活动产生的现金流量净额9.55亿元。截至2011年底,公司总资产为76亿元。

当前,华润三九总市值为180亿元,稳定保持在医药行业上市公司前列。上市公司及所属多家生产制造单元为国家高新技术企业。华润三九先后获评“2008年度中国上市公司百强金牛奖”、“2008年度中国上市公司价值百强”、2009年中国制药工业百强”、“2010年度中国最具竞争力医药上市公司20强”等荣誉。2011年,在中国中药协会发布首批中药行业信用评价结果,华润三九获评AAA级中药企业信用荣誉,荣列排行榜榜首。

经过20多年不懈努力,尤其是并入华润集团四年来的大力变革,华润三九现已发展成为国内大型医药类上市公司。华润三九逐步形成了自身的优势和实力。品牌优势:公司具有较强的细分市场产品品牌运作经验,“999”品牌知名度高,目标客户接受度高,是感冒药和皮肤药市场的领导品牌。近期,由世界第二大传播服务集团WPP发布的《2012中国最具价值品牌TOP50强榜单》中,“999”品牌再度入选其中。此次共有“999”、云南白药、同仁堂3个医药品牌入选。

China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned listed pharmaceutical company, formerly known as Shenzhen Southern pharmaceutical factory. On April 21, 1999, the establishment of a joint stock company was initiated. On March 9, 2000, it was listed on Shenzhen stock exchange with the stock code of 000999. The company officially entered China Resources Group at the end of November 2007. In February 2010, the company name was officially changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". CR 39 is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. "999" brand is a well-known trademark in China. The company's core products have a very high share and popularity in the domestic drug market. Sanjiu Weitai, 999 Ganmaoling, 999 piyanping, 999 paediatric aminophenol, 999 Zhengtian pill, 999 Qiangli loquat dew, Qizhi Weitong granules, 999 Shenfu injection, 999 Shenmai injection, Shuxuening injection, Cinobufacin, 999 Xintailin (cefazolin sodium pentahydrate for injection), 999 traditional Chinese medicine formula granules, etc. the annual sales of each single variety are more than RMB 100 million. Among them, the sales volume of 999 Ganmaoling series ranked first in the cold medicine market for five consecutive years, and achieved a sales volume of 1.36 billion yuan in 2011. In 2011, Cr 39 achieved an operating revenue of 5.525 billion yuan, an increase of 26.58% over the same period of the previous year, and achieved the company's goal of promoting business growth through extensive development. Due to the increase of cost, the net profit attributable to the owners of the parent company was RMB 760 million in 2011, slightly lower than the previous year; the net cash flow from operating activities was RMB 955 million. By the end of 2011, the company's total assets were 7.6 billion yuan. At present, the total market value of Cr 39 is 18 billion yuan, which is stable in the forefront of Listed Companies in the pharmaceutical industry. The listed company and its production and manufacturing units are national high-tech enterprises. China Resources 39 has been awarded the "2008 golden bull award of China's top 100 listed companies", "2008 top 100 value of China's listed companies", "2009 Top 100 pharmaceutical industry of China", "2010 Top 20 most competitive pharmaceutical listed companies of China" and other honors. In 2011, the first batch of credit evaluation results of traditional Chinese medicine industry were released in China Association of traditional Chinese medicine, and Cr 39 won the credit honor of AAA level traditional Chinese medicine enterprise, ranking first in the list. After more than 20 years of unremitting efforts, especially the great changes in four years since it was incorporated into China Resources Group, China Resources 39 has developed into a large-scale pharmaceutical listed company in China. China Resources has gradually formed its own advantages and strength. Brand advantage: the company has strong experience in brand operation of products in the market segment, "999" brand has high popularity and high acceptance of target customers. It is the leading brand in cold medicine and skin medicine market. Recently, in the list of top 50 most valuable brands in China 2012 released by WPP, the world's second largest communication service group, "999" brand has been selected again. This time, "999", Yunnan Baiyao and Tongrentang were selected.

本文链接: https://brand.waitui.com/815c90ce7.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

具身机器人也有自己的保单,险企竞逐机器人保险业务

机器人租赁市场需求旺盛,也催生了大量的保险保障需求。多位业内人士认为,机器人保险作为新型保险产品,其发展成熟需要大量的数据支撑,如果仅与单一企业合作或投保单一设备,数据积累会比较慢。通过与租赁平台等合作,不仅可以获得批量保单,也有利于实现数据的快速积累,为精算定价、风险理赔提供数据支撑,机器人保险有望迎来新增长极。不过,机器人保险在我国还处在起步阶段,发展过程中的风险评估难、产品适配差、责任界定难、风控能力弱等问题,还需要多方协作、共同破局。(上证报)

2小时前

日本11月份实际工资同比下降2.8%,为去年1月以来最大降幅

日本政府周四公布的初步数据显示,受一次性奖金大幅减少的拖累,日本11月份实际工资出现了自去年1月以来的最大降幅。与此同时,通胀超过工资增长的潜在趋势没有改变,这给日本央行带来了挑战。此前日本央行已发出信号,将在今年继续加息。(新浪财经)

2小时前

机构称2026年铜市上行趋势明朗

2025年年末,国内铜现货(电解铜)价格突破100000元/吨关口,为铜市注入强劲动力。与此同时,2026年长单签订博弈进入白热化,国内提价潮、外贸溢价攀升、铜精矿加工费(TC/RC)低位僵持等现象集中出现。业内人士表示,这既反映出市场对供需格局的预判,也预示着2026年铜价或开启新一轮上涨行情。(中证网)

2小时前

中信建投:商业航天产业有望进入新纪元

36氪获悉,中信建投指出,当前商业航天产业在国家政策支持和产业技术突破共同助力下,有望进入新纪元。商业航天产业涉及信息化的主要环节包括(1)遥感及其应用;(2)卫星测运控系统;(3)CAE仿真/卫星测试;(4)星际传输处理模块、通信模组、数据处理平台等;新场景扩展层面关注太空算力。此外,我们认为当前商业航天发展是国企与民营企业共振周期。

2小时前

耐心资本布局硬科技,社保科创基金多地落子

长期资本正在重塑科技创新领域的投资生态。全国社会保障基金理事会官网显示,目前已成立的5只社保科创基金定位均为“服务国家发展的市场化基金”,旨在疏通金融资源进入实体经济的渠道,增加支持科技创新和产业创新深度融合的有效投资,在服务科技强国建设、助力科创企业成长中实现基金安全和保值增值。多位专家介绍,从浙江首发到江苏、福建、湖北、四川相继跟进,社保科创基金的迅速布局,标志着国家长期、耐心资本与区域创新战略的系统性对接已进入加速布局阶段。(上证报)

2小时前

本页详细列出关于999三九的品牌信息,含品牌所属公司介绍,999三九所处行业的品牌地位及优势。
咨询